Earnings summaries and quarterly performance for IONIS PHARMACEUTICALS.
Executive leadership at IONIS PHARMACEUTICALS.
Brett P. Monia
Detailed
Chief Executive Officer
CEO
EL
Elizabeth L. Hougen
Detailed
Executive Vice President, Chief Financial Officer
FB
Frank Bennett
Detailed
Executive Vice President, Chief Scientific Officer
HK
Holly Kordasiewicz
Detailed
Executive Vice President, Chief Development Officer
KJ
Kyle Jenne
Detailed
Executive Vice President, Chief Global Product Strategy Officer
PR
Patrick R. O’Neil
Detailed
Executive Vice President, Chief Legal Officer and General Counsel
RS
Richard S. Geary
Detailed
Executive Vice President, Chief Development Officer
Board of directors at IONIS PHARMACEUTICALS.
AM
Allene M. Diaz
Detailed
Director
BL
B. Lynne Parshall
Detailed
Director
JE
Joan E. Herman
Detailed
Director
JH
Joseph H. Wender
Detailed
Lead Independent Director
JK
Joseph Klein, III
Detailed
Director
JL
Joseph Loscalzo
Detailed
Chairman of the Board
MH
Michael Hayden
Detailed
Director
MY
Michael Yang
Detailed
Director
SR
Spencer R. Berthelsen
Detailed
Director
Research analysts who have asked questions during IONIS PHARMACEUTICALS earnings calls.
Gary Nachman
Raymond James
6 questions for IONS
Also covers: ABBV, ACHV, ADMA +9 more
Jay Olson
Oppenheimer & Co. Inc.
6 questions for IONS
Also covers: ACAD, AMGN, BIIB +23 more
LI
Luca Issi
RBC Capital Markets
6 questions for IONS
Also covers: ADVM, ALLO, ALNY +13 more
JF
Jessica Fye
JPMorgan Chase & Co.
5 questions for IONS
Also covers: ALKS, ALNY, AMRN +23 more
MU
Michael Ulz
Morgan Stanley
5 questions for IONS
Also covers: ALNY, ARWR, FATE +8 more
YZ
Yanan Zhu
Wells Fargo Securities
5 questions for IONS
Also covers: ADAP, AFMD, ARCT +13 more
YW
Yaron Werber
TD Cowen
5 questions for IONS
Also covers: ALEC, AMGN, ARGX +15 more
DL
David Lebowitz
Citigroup Inc.
3 questions for IONS
Also covers: ALNY, ARWR, ASND +11 more
Akash Tewari
Jefferies
2 questions for IONS
Also covers: ALKS, APLS, ARGX +15 more
AC
Andy Chan
Wolfe Research
2 questions for IONS
Also covers: IMVT, INSM
Andy Chen
Wolfe Research, LLC
2 questions for IONS
Also covers: ARGX, CRNX, IMVT +7 more
CM
Chi Meng Fong
BofA Securities
2 questions for IONS
Also covers: BHC, BYSI, EXEL +2 more
Jason Gerberry
Bank of America Merrill Lynch
2 questions for IONS
Also covers: ALKS, AMPH, ARWR +23 more
Joseph Stringer
Needham & Company
2 questions for IONS
Also covers: APLS, CDTX, LXRX +4 more
MR
Maurice Riario
Guggenheim Securities
2 questions for IONS
MU
Mike Ulz
Morgan Stanley
2 questions for IONS
Also covers: ALNY, ARWR, RYTM +1 more
Mitchell Kapoor
H.C. Wainwright & Co.
2 questions for IONS
Also covers: CTMX, HALO, INM +7 more
MM
Myles Minter
William Blair & Company
2 questions for IONS
Also covers: ALEC, ALNY, ARCT +12 more
Salveen Richter
Goldman Sachs
2 questions for IONS
Also covers: ACAD, AGIO, ALLO +21 more
AN
Avi Nova
Morgan Stanley
1 question for IONS
Also covers: VIR
CC
Cassie Chen
RBC Capital Markets
1 question for IONS
Also covers: ARWR, BEAM
Chi
Bank of America
1 question for IONS
Also covers: BHC, GLPG
DC
Debjit Chattopadhyay
Guggenheim Securities
1 question for IONS
Also covers: BEAM, BOLD, HOOK +5 more
Gena Wang
Barclays
1 question for IONS
Also covers: ALNY, BCRX, BLUE +13 more
GW
Gina Wang
Barclays PLC
1 question for IONS
HW
Huidong Wang
Barclays
1 question for IONS
Also covers: ALNY, BCRX, BEAM +15 more
Jacob Roberge
William Blair
1 question for IONS
Also covers: APPN, BL, DDOG +14 more
JG
Jason Gerbery
Bank of America
1 question for IONS
Also covers: VTRS
JW
Jeroen Werber
TD Cowen Inc.
1 question for IONS
LY
Lily Young
Leerink Partners
1 question for IONS
MF
Mani Foroohar
Leerink Partners
1 question for IONS
Also covers: ADVM, ALNY, ARWR +9 more
M
Manoj
Jefferies
1 question for IONS
Also covers: ARVN
SE
Steven Eynav
TD Cowen
1 question for IONS
Zaki Molvi
Jefferies
1 question for IONS
Also covers: BMRN, CYTK
Recent press releases and 8-K filings for IONS.
Ionis Receives Priority Review for Olezarsen sNDA, Prepares for Multiple 2026 Product Launches
IONS
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- The FDA has accepted the supplemental New Drug Application (sNDA) for olezarsen to treat severe hypertriglyceridemia (sHTG) with priority review, setting a PDUFA date of June 30, 2026, and an anticipated June/early July launch.
- Ionis expects three product approvals and launches in 2026: olezarsen for sHTG, zilganersen for Alexander disease, and bepirovirsen for chronic HBV (with partner GSK).
- The company has increased its peak product sales forecast for TRYNGOLZA and sHTG from over $1 billion to over $2 billion , contributing to a projected over $6 billion in potential annual peak product revenue from its owned and partnered medicines.
- Ionis is targeting cash flow break-even by 2028.
1 day ago
Ionis Pharmaceuticals Receives Priority Review for Olezarsen, Anticipates Multiple 2026 Product Launches
IONS
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- The FDA has accepted the supplemental New Drug Application (sNDA) for olezarsen to treat severe hypertriglyceridemia (sHTG) with priority review, setting a PDUFA date of June 30, 2026. Ionis is prepared for a June/early July launch and has already hired a full field team of approximately 200 representatives for this anticipated launch.
- Ionis anticipates three product approvals and launches in 2026: olezarsen for sHTG, zilganersen for Alexander disease (expected launch in H2 2026), and bepirovirsen (partnered with GSK) for chronic HBV (expected approval and launch in multiple markets by end of 2026).
- The company expects to update and improve its revenue guidance at the end of Q1 earnings call, following the priority review for olezarsen, and aims to achieve cash flow break-even by 2028.
- Ionis has increased its peak product sales forecast for TRYNGOLZA and sHTG from over $1 billion to over $2 billion. The company projects over $6 billion in total potential annual peak product revenue, comprising more than $4 billion from Ionis-owned medicines and $2 billion from partnered medicines.
1 day ago
Ionis Pharmaceuticals Receives Priority Review for Olezarsen, Anticipates Multiple 2026 Launches
IONS
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- The FDA has accepted the supplemental New Drug Application (sNDA) for olezarsen to treat severe hypertriglyceridemia (sHTG) with priority review, setting a PDUFA date of June 30, 2026. Ionis is prepared for a launch in June or early July.
- Ionis anticipates three product approvals and launches in 2026: olezarsen for sHTG, zilganersen for Alexander disease, and bepirovirsen for chronic HBV (with partner GSK).
- TRYNGOLZA for familial chylomicronemia syndrome (FCS) generated $108 million in total revenue in its first year of launch. The estimated peak product sales for TRYNGOLZA (FCS/sHTG) have been increased from over $1 billion to over $2 billion.
- The company aims to achieve cash flow break-even by 2028 and projects over $6 billion in total annual peak product revenue from its portfolio.
- Ionis will provide updated financial guidance at its Q1 earnings call, reflecting the impact of the olezarsen priority review.
1 day ago
Ionis Pharmaceuticals Reports Q4 2025 Results and 2026 Outlook
IONS
Earnings
Guidance Update
Product Launch
- Ionis Pharmaceuticals reported strong financial performance for 2025, exceeding its guidance across all metrics, driven by accelerating revenue growth from marketed medicines and R&D collaborations.
- The company provided its financial guidance for 2026, projecting continued revenue growth and a non-GAAP operating loss, while remaining on track to achieve cash flow breakeven by 2028.
- TRYNGOLZA and DAWNZERA demonstrated successful independent launches, with strong early adoption and significant peak sales potential.
- The pipeline advanced significantly, with positive Phase 3 results for Olezarsen and Zilganersen, and multiple data readouts and additional launches anticipated in 2026 from both wholly-owned and partnered programs.
| Metric | FY 2025 | 2026 Guidance |
|---|---|---|
| Revenue ($USD Millions) | $944 | $800 - $825 |
| Revenue Growth (YoY) | 34% | ~20% (adjusted) |
| TRYNGOLZA Product Sales ($USD Millions) | $108 | N/A |
| DAWNZERA Product Sales ($USD Millions) | $8 | N/A |
| Non-GAAP Operating Loss ($USD Millions) | N/A | $500 - $550 |
| Cash and Investments (End of Year) ($USD Millions) | N/A | ~$1,600 |
2 days ago
Ionis Pharmaceuticals Reports Q4 2025 Results and Provides 2026 Guidance
IONS
Earnings
Guidance Update
Product Launch
- Ionis Pharmaceuticals exceeded its 2025 guidance, reporting $944 million in revenues and an operating loss of ($248 million) for the year ended December 31, 2025.
- For 2026, the company projects revenues of $800-$825 million and an operating loss of $500-$550 million, with cash expected to be ~$1.6 billion.
- Olezarsen, with an SNDA submitted, is on track to be launch ready by June 2026 and is anticipated to achieve annual peak product revenue exceeding $2 billion.
- TRYNGOLZA generated $108 million in product sales in 2025, and the launch of DAWNZERA is showing encouraging early momentum.
- The company is also preparing for the anticipated H2 2026 launch of Zilganersen and expects to achieve cash flow breakeven in 2028.
2 days ago
Ionis Pharmaceuticals Reports Strong 2025 Revenue and Provides 2026 Guidance with Multiple Upcoming Product Launches
IONS
Earnings
Guidance Update
Product Launch
- Ionis Pharmaceuticals reported $944 million in total revenue for 2025, marking a 34% increase year-over-year, with $436 million from commercial products and $508 million from R&D collaborations.
- For 2026, the company projects revenue between $800 million and $825 million, an approximate 20% increase year-over-year after adjusting for a one-time license fee, and anticipates a non-GAAP operating loss between $500 million and $550 million.
- TRYNGOLZA generated $108 million in product sales in 2025, including $50 million in Q4, while DAWNZERA contributed $8 million in product sales during its initial months post-launch.
- Ionis expects two additional independent launches in 2026: Olezarsen for severe hypertriglyceridemia (sHTG), with an sNDA submitted and the company launch-ready by June, and Zolgensma for Alexander disease, with an NDA submitted and anticipated launch in the second half of the year.
- The company aims to achieve cash flow breakeven by 2028.
2 days ago
Ionis Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance
IONS
Earnings
Guidance Update
Product Launch
- Ionis Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2025, exceeding its 2025 revenue guidance.
- The company ended 2025 with $2.7 billion in cash, cash equivalents, and short-term investments.
- Ionis provided financial guidance for full year 2026, anticipating continued growth.
- Significant progress was made in its product portfolio, including successful independent launches and advancements in its partnered pipeline with several upcoming regulatory actions and Phase 3 readouts in 2026.
| Metric | Q4 2025 | FY 2025 | FY 2026 Guidance |
|---|---|---|---|
| Total Revenue ($USD Millions) | $203 | $944 | $800 - $825 |
| GAAP Operating Expenses ($USD Millions) | $418 | $1,326 | N/A |
| GAAP Loss from Operations ($USD Millions) | $(215) | $(382) | N/A |
| Non-GAAP Operating Loss ($USD Millions) | $(172) | $(248) | $(500) - $(550) |
| Cash, Cash Equivalents and Short-term Investments ($USD Millions) | N/A | $2,677 | ~$1,600 |
| TRYNGOLZA Net Product Sales ($USD Millions) | $50 | $108 | N/A |
| DAWNZERA Net Product Sales ($USD Millions) | $7 | $8 | N/A |
| SPINRAZA Royalty Revenue ($USD Millions) | $54 | $212 | N/A |
| WAINUA Royalty Revenue ($USD Millions) | $16 | $49 | N/A |
| Sapablursen Upfront Payment ($USD Millions) | N/A | $280 | N/A |
3 days ago
Ionis Reports Q4 and Full Year 2025 Financial Results and 2026 Guidance
IONS
Earnings
Guidance Update
Product Launch
- Ionis Pharmaceuticals reported $944 million in total revenue for the full year 2025, exceeding its financial guidance, and a GAAP operating loss of $382 million.
- The company ended 2025 with $2.7 billion in cash and short-term investments.
- For 2026, Ionis anticipates total revenue of $800-$825 million and a non-GAAP operating loss of $500-$550 million.
- Ionis is preparing for two additional independent launches in 2026, olezarsen and zilganersen, and aims to achieve cash flow breakeven in 2028.
- Key pipeline updates include positive Phase 3 results for bepirovirsen in chronic hepatitis B, with global regulatory filings expected to begin in Q1 2026.
3 days ago
Ionis Pharmaceuticals Announces EU Approval for DAWNZERA™ (donidalorsen)
IONS
Product Launch
New Projects/Investments
- Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the European Commission (EC) has approved DAWNZERA™ (donidalorsen) in the European Union (EU) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
- The approval is based on positive results from Phase 3 studies, which demonstrated a 94% overall mean monthly HAE attack rate reduction at one year in the OASISplus open-label extension study.
- Ionis is eligible for a $15 million milestone payment and tiered royalties of up to 30% on net product sales, as Otsuka holds exclusive rights to bring DAWNZERA to patients across Europe and Asia Pacific.
- DAWNZERA was previously approved by the U.S. Food and Drug Administration in August 2025 for the same indication.
Jan 21, 2026, 12:00 PM
Ionis Highlights Strong 2025 Performance, Pipeline Progress, and Future Revenue Growth
IONS
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- TRYNGOLZA generated $105 million in U.S. product sales in 2025, with $48 million in Q4 2025.
- The annual peak product revenue opportunity for Olezarsen in severe hypertriglyceridemia (sHTG) has been increased to >$2 billion, with a U.S. launch expected in 2026 following SNDA submission to the FDA.
- DAWNZERA received FDA approval on August 21, 2025, for hereditary angioedema (HAE) and is expected to receive EMA approval and launch in Q1 2026.
- Ionis anticipates three product launches in 2026 for Olezarsen (U.S. for sHTG), Zilganersen (U.S. for Alexander disease), and Bepirovirsen (U.S. & Japan for CHB).
- The company projects a clear path to sustained positive cash flow, with 2028 cash flow breakeven and potential annual peak product revenue of >$4 billion from Ionis-owned medicines and >$2 billion from partner medicines.
Jan 13, 2026, 4:15 PM
Quarterly earnings call transcripts for IONIS PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more